20 articles
First study tests whether supervised exercise training is safe and beneficial for bladder cancer patients during treatment.
A completed pilot trial tested physical therapy and progressive muscle relaxation to preserve function and mood in older adults with advanced lung cancer.
A 10-week supervised strength program targets chronic inflammation and self-efficacy in long-term allogeneic HCT survivors.
French researchers test intraperitoneal nivolumab after surgery and heated chemotherapy for advanced ovarian cancer patients.
A pilot trial tested a comprehensive physical, mental, and spiritual intervention for cancer survivors, tracking outcomes at 6 months post-program.
HIIT training studied in 52 men with prostate cancer on active surveillance to evaluate exercise benefits during watchful waiting.
A phase 2 trial tests obinutuzumab, ibrutinib, and venetoclax in Richter's syndrome, a deadly CLL transformation with few treatment options.
Researchers tracked immune changes during intensive radiation treatment to optimize cancer therapy and potential immunotherapy combinations.
A completed trial examines how structured exercise reshapes body composition and sustains physical activity habits in breast cancer patients post-diagnosis.
A Phase 2 trial combining adaptive stereotactic radiotherapy with IMSA101 and checkpoint inhibitors was halted after enrolling only 16 patients.
Researchers tested a new drug combination targeting immune suppression in advanced solid tumors before early termination.
Modified immune cells engineered to overcome cancer's defenses completed safety testing in lymphoma patients.
New study shows how analyzing fluid from lungs can detect cancer mutations and guide personalized treatment decisions.
Innovative immunotherapy approach converts patient tumor cells into personalized vaccines to fight aggressive brain cancer.
Phase 3 trial compared therapeutic vaccine OSE2101 to chemotherapy in 219 lung cancer patients after immunotherapy failure.
A phase II trial explores whether the amino acid L-arginine, with or without enzyme inhibitors, can improve erectile function and quality of life after prostate cancer radiation therapy.
Small trial tests modified immune cells injected directly into chest cavity to fight aggressive cancer with 12-month survival rate.
New viral therapy ASP9801 targets solid tumors directly, potentially offering hope for patients with advanced metastatic cancer.
Small trial tests novel three-drug approach combining immune checkpoint inhibitor, vaccine, and inflammation blocker for metastatic cancers.
A completed phase I trial tests regorafenib plus dual checkpoint inhibitors in 39 patients with hard-to-treat metastatic colorectal cancer.
